Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Withdrawn 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 7Breast 3Lymphoid 2Endocrine 2Tumor-Agnostic 1Other hematologic neoplasm 1Other 1Head & Neck 1Gynecologic 1

Conditions

Breast Neoplasms 3

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lansoprazole × Breast × Clear all
NCT04188119 2025-12-08

IMpALA

The Christie NHS Foundation Trust

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT04874935 2022-11-15

The Possible Efficacy and Safety of Lansoprazole Co-administration With Neoadjuvant Chemotherapy in Women With Breast Cancer

Tanta University

Phase 3 Completed
66 enrolled
Breast

Breast Neoplasms

NCT03794596 2019-07-22

IMpALA

The Christie NHS Foundation Trust

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡